Standard kidney function tests underestimate chronic kidney disease in people with cancer
New research suggests that standard kidney function tests often underestimate chronic kidney disease in cancer patients. This discrepancy can lead to incorrect drug dosing and increased toxicity for patients undergoing chemotherapy.
Why it matters
Improving the accuracy of kidney function assessment is critical for ensuring safe and effective cancer treatment protocols.
edited by Gaby Clark , reviewed by Andrew Zinin
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
Add to Preferred Sources Credit: Unsplash/CC0 Public Domain New research indicates that commonly used measures of kidney function underestimate the prevalence of chronic kidney disease (CKD) in patients with cancer. The findings will be presented at ASN Kidney Week 2026, Oct. 22–25.
In 1,200 adults with solid tumors, investigators compared measured glomerular filtration rate (mGFR), which directly measures kidney filtration rate using a specialized clearance marker, with commonly used estimated GFR (eGFR) values based on the blood proteins cystatin C and creatinine.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in